Eagle Asset Management Inc Fibrogen Inc Transaction History

Eagle Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	SELL	$15.95 - $25.18 $1.19 Million - $1.88 Million	-74,825 Reduced 8.29%	828,307 $15.5 Million
Q4 2022 Feb 14, 2023	BUY	$13.27 - $17.73 $2.18 Million - $2.92 Million	164,502 Added 22.27%	903,132 $14.5 Million
Q3 2022 Nov 07, 2022	BUY	$11.4 - $14.6 $8.42 Million - $10.8 Million	738,630 New	738,630 $9.61 Million
Q2 2019 Aug 05, 2019	SELL	$35.13 - $55.53 $33.3 Million - $52.6 Million	-947,195 Closed	0 $0
Q1 2019 May 01, 2019	BUY	$42.83 - $59.91 $107,460 - $150,314	2,509 Added 0.27%	947,195 $51.5 Million
Q4 2018 Feb 11, 2019	SELL	$37.97 - $60.16 $651,717 - $1.03 Million	-17,164 Reduced 1.78%	944,686 $43.7 Million
Q3 2018 Nov 08, 2018	SELL	$56.3 - $67.25 $554,217 - $662,009	-9,844 Reduced 1.01%	961,850 $58.4 Million
Q2 2018 Aug 07, 2018	BUY	$44.9 - $64.95 $6.81 Million - $9.84 Million	151,574 Added 18.48%	971,694 $60.8 Million
Q1 2018 May 09, 2018	BUY	$45.35 - $61.65 $56,914 - $77,370	1,255 Added 0.15%	820,120 $37.9 Million
Q4 2017 Feb 09, 2018	SELL	$41.95 - $60.1 $443,537 - $635,437	-10,573 Reduced 1.27%	818,865 $39 Million
Q3 2017 Nov 09, 2017	BUY	$33.4 - $53.9 $27.7 Million - $44.7 Million	829,438	829,438 $46.2 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.